

Deloitte Statsautoriseret Revisionspartnerselskab CVR-nr. 33963556 Dokken 8 Postbox 200 6701 Esbjerg

Phone 79 12 84 44 Fax 79 12 84 55 www.deloitte.dk

UR Medicine for Medical Supplies & Laboratories ApS

Haderslevvej 140 6000 Kolding Business Registration No 36721731

Annual report 2017

The Annual General Meeting adopted the annual report on 05.07.2018

Chairman of the General Meeting

Name: Imad Mouse Kadhim Al-Mousa

Contents

	<u>Page</u>
Entity details	2
Statement by Management on the annual report	2
Independent auditor's reports	2
Management commentary	2
Income statement for 2017	2
Balance sheet at 31.12.2017	2
Statement of changes in equity for 2017	2
Notes	2
Accounting policies	2

Entity details

....

Entity

UR Medicine for Medical Supplies & Laboratories ApS Haderslevvej 140 6000 Kolding

Central Business Registration No (CVR): 36721731

Registered in: Kolding

Financial year: 01.01.2017 - 31.12.2017

Executive Board

Imad Mousa Kadhim Al-Mousa

Auditors

Deloitte Statsautoriseret Revisionspartnerselskab Dokken 8 Postbox 200 6701 Esbjerg

Statement by Management on the annual report

Executive Board have today considered and approved the annual report of UR Medicine for Medical Supplies & Laboratories ApS for the financial year 01.01.2017 - 31.12.2017.

The annual report is presented in accordance with the Danish Financial Statements Act.

In my opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.

I believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

I recommend the annual report for adoption at the Annual General Meeting.

Kolding, 05.07.2018

Executive Board

Imad Mousa Kadhim Al-Mousa

Independent auditor's reports

To the shareholders of UR Medicine for Medical Supplies & Laboratories ApS Report on extended review of the financial statements

We have performed an extended review of the financial statements of UR Medicine for Medical Supplies & Laboratories ApS for the financial year 01.01.2017 - 31.12.2017. The financial statements, which comprise the income statement, balance sheet, statement of changes in equity, notes and accounting policies, are prepared in accordance with the Danish Financial Statements Act.

Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on the financial statements. We conducted our extended review in accordance with the assurance engagement standard for small enterprises as issued by the Danish Business Authority and the standard on extended review of financial statements prepared in accordance with the Danish Financial Statements Act as issued by FSR - Danish Auditors.

This requires that we comply with the Danish Public Accountants Act and FSR – Danish Auditors' Code of Conduct and plan and perform procedures to obtain limited assurance about our opinion on the financial statements and that we perform specifically required supplementary procedures for the purpose of obtaining additional assurance about our opinion.

An extended review consists of making inquiries, primarily of management and, if appropriate, of other entity personnel, performing analytical procedures and specifically required supplementary procedures as well as evaluating the evidence obtained.

The procedures performed in an extended review are less in scope than in an audit, and accordingly we do not express an audit opinion on the financial statements.

Conclusion

Based on our extended review, in our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017 in accordance with the Danish Financial Statements Act.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

Independent auditor's reports

In connection with our extended review of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the extended review or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Esbjerg, 05.07.2018

Deloitte

Statsautoriseret Revisionspartnerselskab Central Business Registration No (CVR) 33963556

Anders Rasmussen State Authorised Public Accountant Identification No (MNE) mne34316

Management commentary

Primary activities

The Company's purpose is to do business with articles on health care and according to the Executive Borad's discretion in business related thereto.

Development in activities and finances

The Company's loss is DKK 798k, which not is satisfying.

The primary reason to the loss, are the development in the USD exchange rate, high marketing and administrative costs.

Events after the balance sheet date

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

Income statement for 2017

	<u>Notes</u>	2017 DKK	2015 DKK
Gross profit/loss		(380.355)	5.307.290
Other financial income	2	9.960	35.931
Other financial expenses	3	(652.968)	(41.866)
Profit/loss before tax		(1.023.363)	5.301.355
Tax on profit/loss for the year	4	225.140	(1.151.739)
Profit/loss for the year		(798.223)	4.149.616
Proposed distribution of profit/loss			
Ordinary dividend for the financial year		0	500.000
Retained earnings		(798.223)	3.649.616
		(798.223)	4.149.616

Balance sheet at 31.12.2017

2017 2015 DKK DKK Notes Manufactured goods and goods for resale 4.934.277 0 **Inventories** 4.934.277 0 Trade receivables 3.461.506 1.622.153 Receivables from group enterprises 13.750 0 2.266.063 Other receivables 74 Joint taxation contribution receivable 225.140 Receivables 3.888.216 3.700.470 Cash 7.859 1.433.534 **Current assets** 8.642.606 5.321.750 **Assets** 8.642.606 5.321.750

Balance sheet at 31.12.2017

_	Notes	2017 DKK	2015 DKK
Contributed capital		50.000	50.000
Retained earnings		2.002.695	2.800.918
Proposed dividend		0	500.000
Equity		2.052.695	3.350.918
Trade payables		4.776.696	0
Payables to group enterprises		1.776.215	1.000.003
Payables to shareholders and management		2.000	2.000
Joint taxation contribution payable		0	933.829
Other payables		35.000	35.000
Current liabilities other than provisions		6.589.911	1.970.832
Liabilities other than provisions		6.589.911	1.970.832
Equity and liabilities		8.642.606	5.321.750

Staff costs 1

Statement of changes in equity for 2017

	Contributed capital	Retained earnings DKK	Proposed dividend DKK	Total DKK
Equity beginning of year	50.000	2.800.918	500.000	3.350.918
Ordinary dividend paid	0	0	(500.000)	(500.000)
Profit/loss for the year	0	(798.223)	0	(798.223)
Equity end of year	50.000	2.002.695	0	2.052.695

Notes

-

	2017	2015
1. Staff costs		
Average number of employees	<u> </u>	<u> </u>
	2017	2015
	<u>DKK</u>	DKK
2. Other financial income		
Exchange rate adjustments	9.960	35.931
	9.960	35.931
	2017	2015
	DKK	DKK
3. Other financial expenses		
Financial expenses from group enterprises	47.539	39.610
Other interest expenses	1.105	81
Exchange rate adjustments	602.405	0
Other financial expenses	1.919	2.175
	652.968	41.866
	2017	2015
	DKK	DKK
4. Tax on profit/loss for the year		
Current tax	0	933.829
Change in deferred tax	0	234.000
Adjustment concerning previous years	0	(16.090)
Refund in joint taxation arrangement	(225.140)	0
	(225.140)	1.151.739

Accounting policies

Reporting class

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of certain provisions for report-ing class C.

The accounting policies applied to these financial statements are consistent with those applied last year.

Income statement

Gross profit or loss

Gross profit or loss comprises revenue, other operating income and external expenses.

Revenue

Revenue from the sale of services is recognised in the income statement when delivery is made to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.

Other external expenses

Other external expenses include expenses relating to the Entity's ordinary activities, including expenses for premises, stationery and office supplies, administrative costs, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.

Other financial income

Other financial income comprises dividends etc received on other investments, interest income, including interest income on receivables from group enterprises, net capital gains on securities, payables and transactions in foreign currencies, amortisation of financial assets as well as tax relief under the Danish Tax Prepayment Scheme etc.

Other financial expenses

Other external expenses include expenses relating to the Entity's ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc

Tax on profit/loss for the year

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.

Balance sheet

Inventories

Inventories are measured at the lower of cost using the FIFO method and net realisable value.

The net realisable value of inventories is calculated as the estimated selling price less completion costs and costs incurred to execute sale.

Accounting policies

Receivables

Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.

Joint taxation contributions receivable or payable

Current joint taxation contributions payable or joint taxation contributions receivable are recognised in the balance sheet, calculated as tax computed on the taxable income for the year, which has been adjusted for prepaid tax. For tax losses, joint taxation contributions receivable are only recognised if such losses are expected to be used under the joint taxation arrangement.

Cash

Cash comprises cash in hand and bank deposits.

Dividend

Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity.

Other financial liabilities

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.